Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

Pragya Srivastava, Benjamin E. Paluch, Junko Matsuzaki, Smitha R. James, Golda Collamat-Lai, Julia Karbach, Michael J. Nemeth, Pietro Taverna, Adam R Karpf, Elizabeth A. Griffiths

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The mechanism of clinical action for the FDA approved hypomethylating drugs azacitidine and decitabine remains unresolved and in this context the potential immunomodulatory effect of these agents on leukemic cells is an area of active investigation. Induced expression of methylated Cancer Testis Antigen (CTA) genes has been demonstrated in leukemic cell lines following exposure to hypomethylating drugs in vitro. SGI-110 is a novel hypomethylating dinucleotide with prolonged in vivo exposure and clinical activity in patients with MDS and AML. We demonstrate that this agent, like decitabine, produces robust re-expression of the CTAs NY-ESO-1 and MAGE-A, both in vitro and in leukemia-bearing AML xenografts. Upregulation of these genes in vitro was sufficient to induce cytotoxicity by HLA-compatible CD8+ T-cells specific for NY-ESO-1, a well-recognized and immunogenic CTA. Additionally, exposure to SGI-110 enhances MHC class I and co-stimulatory molecule expression, potentially contributing to recognition of CTAs. SGI-110, like the parent compound decitabine, induces expression of CTAs and might modulate immune recognition of myeloid malignancy.

Original languageEnglish (US)
Pages (from-to)1332-1341
Number of pages10
JournalLeukemia Research
Volume38
Issue number11
DOIs
StatePublished - Nov 1 2014

Fingerprint

decitabine
Myeloid Cells
Heterografts
Acute Myeloid Leukemia
Testicular Neoplasms
Azacitidine
Antigens
Pharmaceutical Preparations
Genes
Leukemia
Up-Regulation
T-Lymphocytes
Cell Line
In Vitro Techniques
SGI-110
Neoplasms

Keywords

  • Acute myeloid leukemia
  • Cancer germline genes
  • Cancer testis antigens
  • DNA methylation
  • DNA methyltransferase inhibitors
  • Epigenetics
  • Immune modulation
  • SGI-110

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Srivastava, P., Paluch, B. E., Matsuzaki, J., James, S. R., Collamat-Lai, G., Karbach, J., ... Griffiths, E. A. (2014). Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leukemia Research, 38(11), 1332-1341. https://doi.org/10.1016/j.leukres.2014.09.001

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. / Srivastava, Pragya; Paluch, Benjamin E.; Matsuzaki, Junko; James, Smitha R.; Collamat-Lai, Golda; Karbach, Julia; Nemeth, Michael J.; Taverna, Pietro; Karpf, Adam R; Griffiths, Elizabeth A.

In: Leukemia Research, Vol. 38, No. 11, 01.11.2014, p. 1332-1341.

Research output: Contribution to journalArticle

Srivastava, P, Paluch, BE, Matsuzaki, J, James, SR, Collamat-Lai, G, Karbach, J, Nemeth, MJ, Taverna, P, Karpf, AR & Griffiths, EA 2014, 'Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts', Leukemia Research, vol. 38, no. 11, pp. 1332-1341. https://doi.org/10.1016/j.leukres.2014.09.001
Srivastava P, Paluch BE, Matsuzaki J, James SR, Collamat-Lai G, Karbach J et al. Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. Leukemia Research. 2014 Nov 1;38(11):1332-1341. https://doi.org/10.1016/j.leukres.2014.09.001
Srivastava, Pragya ; Paluch, Benjamin E. ; Matsuzaki, Junko ; James, Smitha R. ; Collamat-Lai, Golda ; Karbach, Julia ; Nemeth, Michael J. ; Taverna, Pietro ; Karpf, Adam R ; Griffiths, Elizabeth A. / Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts. In: Leukemia Research. 2014 ; Vol. 38, No. 11. pp. 1332-1341.
@article{b3cdbc99ea224a71af23f96d88aed0e7,
title = "Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts",
abstract = "The mechanism of clinical action for the FDA approved hypomethylating drugs azacitidine and decitabine remains unresolved and in this context the potential immunomodulatory effect of these agents on leukemic cells is an area of active investigation. Induced expression of methylated Cancer Testis Antigen (CTA) genes has been demonstrated in leukemic cell lines following exposure to hypomethylating drugs in vitro. SGI-110 is a novel hypomethylating dinucleotide with prolonged in vivo exposure and clinical activity in patients with MDS and AML. We demonstrate that this agent, like decitabine, produces robust re-expression of the CTAs NY-ESO-1 and MAGE-A, both in vitro and in leukemia-bearing AML xenografts. Upregulation of these genes in vitro was sufficient to induce cytotoxicity by HLA-compatible CD8+ T-cells specific for NY-ESO-1, a well-recognized and immunogenic CTA. Additionally, exposure to SGI-110 enhances MHC class I and co-stimulatory molecule expression, potentially contributing to recognition of CTAs. SGI-110, like the parent compound decitabine, induces expression of CTAs and might modulate immune recognition of myeloid malignancy.",
keywords = "Acute myeloid leukemia, Cancer germline genes, Cancer testis antigens, DNA methylation, DNA methyltransferase inhibitors, Epigenetics, Immune modulation, SGI-110",
author = "Pragya Srivastava and Paluch, {Benjamin E.} and Junko Matsuzaki and James, {Smitha R.} and Golda Collamat-Lai and Julia Karbach and Nemeth, {Michael J.} and Pietro Taverna and Karpf, {Adam R} and Griffiths, {Elizabeth A.}",
year = "2014",
month = "11",
day = "1",
doi = "10.1016/j.leukres.2014.09.001",
language = "English (US)",
volume = "38",
pages = "1332--1341",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

AU - Srivastava, Pragya

AU - Paluch, Benjamin E.

AU - Matsuzaki, Junko

AU - James, Smitha R.

AU - Collamat-Lai, Golda

AU - Karbach, Julia

AU - Nemeth, Michael J.

AU - Taverna, Pietro

AU - Karpf, Adam R

AU - Griffiths, Elizabeth A.

PY - 2014/11/1

Y1 - 2014/11/1

N2 - The mechanism of clinical action for the FDA approved hypomethylating drugs azacitidine and decitabine remains unresolved and in this context the potential immunomodulatory effect of these agents on leukemic cells is an area of active investigation. Induced expression of methylated Cancer Testis Antigen (CTA) genes has been demonstrated in leukemic cell lines following exposure to hypomethylating drugs in vitro. SGI-110 is a novel hypomethylating dinucleotide with prolonged in vivo exposure and clinical activity in patients with MDS and AML. We demonstrate that this agent, like decitabine, produces robust re-expression of the CTAs NY-ESO-1 and MAGE-A, both in vitro and in leukemia-bearing AML xenografts. Upregulation of these genes in vitro was sufficient to induce cytotoxicity by HLA-compatible CD8+ T-cells specific for NY-ESO-1, a well-recognized and immunogenic CTA. Additionally, exposure to SGI-110 enhances MHC class I and co-stimulatory molecule expression, potentially contributing to recognition of CTAs. SGI-110, like the parent compound decitabine, induces expression of CTAs and might modulate immune recognition of myeloid malignancy.

AB - The mechanism of clinical action for the FDA approved hypomethylating drugs azacitidine and decitabine remains unresolved and in this context the potential immunomodulatory effect of these agents on leukemic cells is an area of active investigation. Induced expression of methylated Cancer Testis Antigen (CTA) genes has been demonstrated in leukemic cell lines following exposure to hypomethylating drugs in vitro. SGI-110 is a novel hypomethylating dinucleotide with prolonged in vivo exposure and clinical activity in patients with MDS and AML. We demonstrate that this agent, like decitabine, produces robust re-expression of the CTAs NY-ESO-1 and MAGE-A, both in vitro and in leukemia-bearing AML xenografts. Upregulation of these genes in vitro was sufficient to induce cytotoxicity by HLA-compatible CD8+ T-cells specific for NY-ESO-1, a well-recognized and immunogenic CTA. Additionally, exposure to SGI-110 enhances MHC class I and co-stimulatory molecule expression, potentially contributing to recognition of CTAs. SGI-110, like the parent compound decitabine, induces expression of CTAs and might modulate immune recognition of myeloid malignancy.

KW - Acute myeloid leukemia

KW - Cancer germline genes

KW - Cancer testis antigens

KW - DNA methylation

KW - DNA methyltransferase inhibitors

KW - Epigenetics

KW - Immune modulation

KW - SGI-110

UR - http://www.scopus.com/inward/record.url?scp=84910087763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910087763&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2014.09.001

DO - 10.1016/j.leukres.2014.09.001

M3 - Article

C2 - 25260825

AN - SCOPUS:84910087763

VL - 38

SP - 1332

EP - 1341

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 11

ER -